Report cover image

Chemotherapy-Induced Peripheral Neuropathy (CIPN): Market View

Publisher GlobalData
Published Mar 19, 2026
Length 97 Pages
SKU # GBDT21150988

Description

Chemotherapy-Induced Peripheral Neuropathy (CIPN): Market View

Summary

This reports provides a data-driven overview of the current and future competitive landscape in Chemotherapy-Induced Peripheral Neuropathy Therapeutics.
  • In 2024 and 2029, China is anticipated to have the highest number of diagnosed incident cases of CIPN, representing a large portion of global cases.
  • Currently, the CIPN has no disease-modifying therapies or nerve regenerative strategies that halt nerve damage, promote regeneration, or reverse established neuropathy.
  • The CIPN pipeline holds 60 molecules, with no assets in the pre-registration stage, four assets in Phase III development, and another 11 in Phase II.
  • OOver the past decade, 218 clinical trials were conducted in CIPN. The year with the most studies initiated was 2022, with 35 trials, followed by 2024 with 25 trials.
  • The CIPN market is unlikely to see an influx of drugs in the near term, with no products in pre-registration and only four products in Phase III development.
Scope

GlobalData’s Chemotherapy-Induced Peripheral Neuropathy: Market View combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include:
  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Breakdown by Mechanism of Action, Route of Administration
  • Product Profiles with Sales Forecast
  • Pricing and Reimbursement Assessment
  • Annual Therapy Cost
  • Time to Pricing and Time to Reimbursement
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Mergers, Acquisitions, and Strategic Alliances by Region
  • Overview of Recent Deals
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts
Reasons to Buy
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the Chemotherapy-Induced Peripheral Neuropathy Therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Chemotherapy-Induced Peripheral Neuropathy Therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

97 Pages
1 Preface
1.1 Contents
1.2 Report Scope
1.3 List of Tables and Figures
1.4 Abbreviations
2 Key Findings
3 Disease Landscape
3.1 Disease Overview
3.2 Epidemiology Overview
3.3 Treatment Overview
4 Marketed Drugs Assessment
4.1 Leading Marketed Drugs
4.2 Overview by Mechanism of Action
4.3 Overview by Molecule Type
4.4 Product Profile and Sales Forecast
5 Pricing and Reimbursement Assessment
6 Pipeline Drugs Assessment
6.1 Pipeline Drugs
6.2 Overview by Development Stage
6.3 Overview by Mechanism of Action
6.4 Overview by Molecule Type
6.5 Product Profile and Sales Forecast
6.6 Drug-specific PTSR and LoA
6.7 Indication-specific and Therapy Area-specific PTSR and LoA
7 Clinical Trials Assessment
7.1 Historical Overview
7.2 Overview by Phase
7.3 Overview by Status
7.4 Overview by Phase for Ongoing and Planned Trials
7.5 Trials with Virtual Components
7.6 Top 20 Biomarkers by Trial Phase
7.7 Overview of Trials by Geography
7.8 Single-Country and Multinational Trials by Region
7.9 Top 20 Sponsors with Breakdown by Phase
7.10 Top 20 Sponsors with Breakdown by Status
7.11 Overview by Endpoint Status
7.12 Overview by Race and Ethnicity
7.13 Enrollment Data
7.14 Top 20 countries for Trial Sites
7.15 Top 20 Sites Globally
7.16 Feasibility Analysis - Geographic Overview
7.17 Feasibility Analysis - Benchmark Models
8 Deals Landscape
8.1 Mergers, Acquisitions, and Strategic Alliances by Region
8.2 Recent Mergers, Acquisitions, and Strategic Alliances
9 Commercial Assessment
9.1 Key Market Players
10 Future Market Catalysts
11 Appendix
11.1 Methodology
11.2 Methodology - Sales Forecast
11.3 Methodology - Pricing and Reimbursement
11.4 Methodology - PTSR and LoA Analysis
11.5 About the Authors
11.6 Contact Us
11.7 Disclaimer

Search Inside Report

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us